Lascarrou J B, Muller Gregoire, Quenot Jean-Pierre, Massart Nicolas, Landais Mickael, Asfar Pierre, Frat Jean-Pierre, Chakarian Jean-Charles, Sirodot Michel, Francois Bruno, Grillet Guillaume, Vimeux Sylvie, Delahaye Arnaud, Legriel Stéphane, Thevenin Didier, Reignier Jean, Colin Gwenhael
Medical Intensive Care Unit, Service de Médecine Intensive Réanimation, University Hospital Center, 30 Boulevard Jean Monnet, 44093, Paris, France.
Paris Cardiovascular Research Center, INSERM U970, Paris, France.
Ann Intensive Care. 2021 Nov 14;11(1):156. doi: 10.1186/s13613-021-00947-w.
Few data are available about outcomes of patients screened for, but not enrolled in, randomised clinical trials.
We retrospectively reviewed patients who had non-inclusion criteria for the HYPERION trial comparing 33 °C to 37 °C in patients comatose after cardiac arrest in non-shockable rhythm, due to any cause. A good neurological outcome was defined as a day-90 Cerebral Performance Category score of 1 or 2.
Of the 1144 patients with non-inclusion criteria, 1130 had day-90 information and, among these, 158 (14%) had good functional outcomes, compared to 7.9% overall in the HYPERION trial (10.2% with and 5.7% without hypothermia). Considerable centre-to-centre variability was found in the proportion of non-included patients who received hypothermia (0% to 83.8%) and who had good day-90 functional outcomes (0% to 31.3%). The proportion of patients with a good day-90 functional outcome was significantly higher with than without hypothermia (18.5% vs. 11.9%, P = 0.003).
Our finding of better functional outcomes without than with inclusion in the HYPERION trial, despite most non-inclusion criteria being of adverse prognostic significance (e.g., long no-flow and low-flow times and haemodynamic instability), raises important questions about the choice of patient selection criteria and the applicability of trial results to everyday practice. At present, reserving hypothermia for patients without predictors of poor prognosis seems open to criticism.
关于接受随机临床试验筛查但未入组患者的预后数据较少。
我们回顾性分析了因任何原因导致非可电击心律心脏骤停后昏迷的患者,这些患者不符合HYPERION试验(比较33°C与37°C)的纳入标准。良好的神经功能预后定义为90天时脑功能分类评分为1或2。
在1144例不符合纳入标准的患者中,1130例有90天的信息,其中158例(14%)有良好的功能预后,而HYPERION试验总体为7.9%(体温过低组为10.2%,非体温过低组为5.7%)。在未纳入的患者中,接受体温过低治疗的比例(0%至83.8%)以及90天功能预后良好的比例(0%至31.3%)在各中心之间存在显著差异。90天功能预后良好的患者比例,体温过低组显著高于非体温过低组(18.5%对11.9%,P = 0.003)。
我们发现,尽管大多数排除标准具有不良预后意义(如长时间无血流和低血流时间以及血流动力学不稳定),但未纳入HYPERION试验的患者功能预后比纳入试验的患者更好,这引发了关于患者选择标准的选择以及试验结果在日常实践中的适用性的重要问题。目前,将体温过低治疗保留给无预后不良预测因素的患者似乎值得商榷。